We then decided to test the activity of the scDb on a panel of TRAIL-R2+ tumor cell lines of different origins and characterized by different TRAIL-R2 expression levels as well as different sensitivity to sTRAIL (Table 2). Here, TNFRSF10B is linked to neoplasm.